| Trial ID: | L0028 |
| Source ID: | NCT02217345
|
| Associated Drug: |
Growth Hormone
|
| Title: |
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
|
| Acronym: |
NAFLD
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Fatty Liver Disease (NAFLD)
|
| Interventions: |
Drug: Growth hormone|Drug: Placebo
|
| Outcome Measures: |
Intrahepatic lipid content as measured by 1H-MRS|Inflammatory Markers
|
| Sponsor/Collaborators: |
Massachusetts General Hospital
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Not applicable
|
| Enrollment: |
53
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
September 2015
|
| Completion Date: |
September 13, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 26, 2021
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02217345
|
